CoChat

Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis

Open access
Hu, Jiao, Chen, Jin-bo, Cui, Yu, Zhu, Ye-wen, Ren, Wen-biao, Zhou, Xu, Liu, Long-fei, Chen, He-qun, Zu, Xiong-bing · 2018 · Medicine

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Recent clinical trials indicated that metformin intake might play a protective role in the incidence and oncologic outcomes of various cancers. However, its protective effect on bladder cancer remains uncertain. METHODS: We performed a meta-analysis to investigate the association between metformin intake and bladder cancer risk as well as oncologic outcomes in diabetes mellitus (DM) patients. A comprehensive literature search was performed using PubMed, Embase, and the Cochrane Central Search Library in December 2017. Hazard ratio (HR) with 95% confidence interval (CI) was pooled. RESULTS: A total of 9 retrospective cohort studies with 1,270,179 patients were included. A meta-analysis revealed that metformin intake was associated with an increased recurrence-free survival (HR = 0.55, 95% confidence interval [CI] = 0.35-0.88; P = .01; I = 64%), improved progression-free survival (HR = 0.70, 95% CI = 0.51-0.96; P = .03; I = 33%), and prolonged cancer-specific survival (HR = 0.57, 95% CI = 0.40-0.81; P = .002; I = 0%). However, results demonstrated that metformin intake was not associated with a decreased incidence of bladder cancer (HR = 0.82, 95% CI = 0.61-1.09; P = .17; I = 85%) or an increased overall survival in bladder cancer patients (HR = 0.83, 95% CI = 0.47-1.44; P = .50; I = 64%). CONCLUSION: The present meta-analysis indicated that metformin intake could improve the prognosis of bladder cancer patients. Further prospective cohort studies and mechanistic studies are still required to determine the precise role of metformin in the initiation and progression of bladder cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000011596

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of studies selection. HR = hazard ratio.
Figure 1 Flow chart of studies selection. HR = hazard ratio.CC BY · PubMed Central
Figure 2 Forest plot of hazard ratio for bladder cancer incidence in patients with type 2 diabetes mellitus. CI = confidence interval, SE = standard error.
Figure 2 Forest plot of hazard ratio for bladder cancer incidence in patients with type 2 diabetes mellitus. CI = confidence interval, SE = standard error.CC BY · PubMed Central
Figure 3 Forest plot of HR for recurrence-free and progress-free survival. (A) Association between metformin intake and recurrence-free survival sub-grouped by tumor stage; (B) association between metformin intake and recurrence-free survival sub-grouped by ethnicity; (C) association between metformin intake and progression-free survival. The diamond indicates the pooled HR value. CI = confidence interval, HR = hazard ratio, MIBC = muscle invasive bladder cancer, NMIBC = non-muscle invasive bladder cancer, SE = standard error.
Figure 3 Forest plot of HR for recurrence-free and progress-free survival. (A) Association between metformin intake and recurrence-free survival sub-grouped by tumor stage; (B) association between metformin intake and recurrence-free survival sub-grouped by ethnicity; (C) association between metformin intake and progression-free survival. The diamond indicates the pooled HR value. CI = confidence interval, HR = hazard ratio, MIBC = muscle invasive bladder cancer, NMIBC = non-muscle invasive bladder cancer, SE = standard error.CC BY · PubMed Central
Figure 4 Forest plot of HR for overall survival and cancer-specific survival. (A) Association between metformin intake and overall survival; (B) Association between metformin intake and cancer-specific survival. The diamond indicates the pooled HR value. CI = confidence interval, SE = standard error.
Figure 4 Forest plot of HR for overall survival and cancer-specific survival. (A) Association between metformin intake and overall survival; (B) Association between metformin intake and cancer-specific survival. The diamond indicates the pooled HR value. CI = confidence interval, SE = standard error.CC BY · PubMed Central
Figure 5 Sensitivity analysis for (A) the incidence, (B) recurrence-free survival, (C) progression-free survival, (D) cancer-specific survival, and (E) overall survival.
Figure 5 Sensitivity analysis for (A) the incidence, (B) recurrence-free survival, (C) progression-free survival, (D) cancer-specific survival, and (E) overall survival.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 56

Metadata

Authors
Hu, J., Chen, J.-B., Cui, Y., Zhu, Y.-W., Ren, W.-B., Zhou, X., Liu, L.-F., Chen, H.-Q., & Zu, X.-B.
Affiliations
Central South University (CN)
Venue
Medicine
Published
2018-07
Volume
97
Issue
30
Pages
e11596
ISSN
0025-7974 (ISSN-L)
OpenAlex
W2884549606
Cited by
56
References
49
Citations by year
2026: 6 · 2025: 3 · 2024: 4 · 2023: 11 · 2022: 9 · 2021: 10 · 2020: 7 · 2019: 6
FWCI
0.56
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
metformin, bladder cancer, type 2 diabetes, cancer risk, oncological outcomes, recurrence-free survival, progression-free survival, cancer-specific survival, overall survival, drug repurposing
MeSH terms
Aged, Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Proportional Hazards Models, Disease Progression, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1097/md.0000000000011596
The paper
Hu, J., Chen, J.-B., Cui, Y., Zhu, Y.-W., Ren, W.-B., Zhou, X., Liu, L.-F., Chen, H.-Q., & Zu, X.-B. (2018). Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Medicine. https://doi.org/10.1097/md.0000000000011596

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.